USPTO-FDA Joint Engagements

Dr. Robert Califf, Commissioner of Food and Drugs, delivering remarks, and Kathi Vidal, USPTO Director
Take a look at our photo gallery of past events.

On July 9, 2021, President Biden signed Executive Order (EO) 14036 on “Promoting Competition in the American Economy." In response, the U.S. Food and Drug Administration (FDA) and the U.S. Patent and Trademark Office (USPTO) have agreed to collaborate to ensure that our system supports meaningful innovation in drug development and a competitive marketplace with greater access to medicines for American families. 

To encourage feedback about these collaboration initiatives, the USPTO and the FDA are hosting joint events in which the public can learn about existing proposals, ask questions, and comment on areas for collaboration and engagement between the agencies.

You can find upcoming and past USPTO-FDA engagement events on this page. You can also view their agendas and listen to recordings of previous events by selecting them.

Past events

USPTO and FDA held a cross-training event to share information about types of patents, standards for patentability, the patent examination process, and publicly accessible patent records.

USPTO and FDA held a cross-training event to share information about drug approval pathways, information disclosure policies and practices, and FDA's publicly available databases.

Join USPTO panelists and a practitioner moderator for a discussion for the July 29, 2022, Federal Register notice on duty of disclosure and duty of reasonable inquiry.

USPTO and FDA held a joint public listening session to hear public input on areas for collaboration and engagement between the agencies.

USPTO held a Webinar to provide guidance on how to submit comments in response to the Request for Comments on Initiatives to Ensure the Robustness and Reliability of Patent Rights.

USPTO and FDA held a cross-training event to share information about examination and post-grant proceedings at USPTO.